Stoke Therapeutics Inc (STOK)

Nov 22, 2025

Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN

Nov 22, 2025

Nov 22, 2025

Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK) - MarketBeat

Nov 22, 2025

Nov 22, 2025

Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat

Nov 22, 2025

Nov 21, 2025

(STOK) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

Nov 21, 2025

Nov 21, 2025

Why Stoke Therapeutics Inc. stock remains undervaluedMarket Risk Report & Short-Term High Return Ideas - newser.com

Nov 21, 2025

Nov 21, 2025

Can Stoke Therapeutics Inc. stock sustain institutional interest2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com

Nov 21, 2025

Nov 20, 2025

How Stoke Therapeutics Inc. stock valuations compare to rivalsProduct Launch & Verified Momentum Stock Alerts - newser.com

Nov 20, 2025

Nov 20, 2025

Can Stoke Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Report & High Conviction Buy Zone Alerts - newser.com

Nov 20, 2025

Nov 19, 2025

Can Stoke Therapeutics Inc. stock resist sector downturns2025 Top Decliners & Intraday High Probability Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Director Adrian Krainer Sells 40,472 Shares - MarketBeat

Nov 19, 2025

Nov 19, 2025

Does Stoke Therapeutics Inc. show high probability of reboundJuly 2025 Gainers & Weekly High Return Forecasts - newser.com

Nov 19, 2025

Nov 19, 2025

Is Stoke Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Weekly High Conviction Ideas - newser.com

Nov 19, 2025

Nov 19, 2025

Live market analysis of Stoke Therapeutics Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com

Nov 19, 2025

Nov 19, 2025

Why Stoke Therapeutics Inc. stock attracts high net worth investorsBear Alert & Fast Moving Stock Trade Plans - newser.com

Nov 19, 2025

Nov 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6%Still a Buy? - MarketBeat

Nov 19, 2025

Nov 19, 2025

Will Stoke Therapeutics Inc. stock maintain momentum in 20252025 Analyst Calls & Risk Managed Investment Signals - newser.com

Nov 19, 2025

Nov 19, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener

Nov 19, 2025

Nov 19, 2025

19,300 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Integrated Quantitative Investments LLC - MarketBeat

Nov 19, 2025

Nov 19, 2025

Los Angeles Capital Management LLC Makes New $224,000 Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat

Nov 19, 2025

Nov 19, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)November 18, 2025 - BioSpace

Nov 19, 2025

Nov 18, 2025

What technical models suggest about Stoke Therapeutics Inc.’s comeback2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com

Nov 18, 2025

Nov 18, 2025

Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 18, 2025

Nov 18, 2025

Stoke Therapeutics Director Adrian R. Krainer Sells Over 40,000 Shares - TradingView

Nov 18, 2025

Nov 18, 2025

Dir Krainer Sells 40,472 ($1.1M) Of Stoke Therapeutics Inc [STOK] - TradingView

Nov 18, 2025

Nov 18, 2025

[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 18, 2025

Nov 18, 2025

Could Endpoint Choices in the EMPEROR Trial Reveal a Strategic Shift for Stoke Therapeutics (STOK)? - simplywall.st

Nov 18, 2025

Nov 17, 2025

Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Stu - GuruFocus

Nov 17, 2025

Nov 17, 2025

Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study - GuruFocus

Nov 17, 2025

Nov 17, 2025

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - The Manila Times

Nov 17, 2025

Nov 17, 2025

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire

Nov 17, 2025

Nov 16, 2025

Exit strategy if you’re trapped in Stoke Therapeutics Inc.July 2025 Action & Fast Momentum Stock Entry Tips - newser.com

Nov 16, 2025

Nov 16, 2025

Using portfolio simulators with Stoke Therapeutics Inc. includedJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com

Nov 16, 2025